AZ-NHIS’s dramatic conclusion on Tagrisso drug price negotiation

Published: 2017-11-09 16:30:00
Updated: 2017-11-09 16:02:09

The AstraZeneca’s non-small cell lung cancer treatment Tagrisso(generic name: osimertinib), whose negotiation was broken down twice, finally passed the drug price negotiation.

The National Health Insurance Service(NHIS) and AstraZeneca Korea have dramatically concluded the 3rd drug price negotia...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.